penicillamine has been researched along with Angiogenesis, Pathologic in 10 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of copper (Cu)-depletion diet and D-penicillamine treatment (CDPT) on both tumor growth and angiogenesis, we studied Fischer-344 rats in which 9L gliosarcoma cells had been subcutaneously implanted." | 3.69 | Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. ( Ikeda, Y; Nakazawa, S; Yoshida, D, 1995) |
| "Glioblastoma is a highly vascularized brain tumor, and antiangiogenic therapy improves its progression-free survival." | 1.39 | Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. ( Jiang, A; Jiang, E; Kieran, MW; Mammoto, A; Mammoto, T; Panigrahy, D, 2013) |
| "Trientine treatment resulted in a marked suppression of neovascularization and increase of apoptosis in the tumor, whereas tumor cell proliferation itself was not altered." | 1.31 | The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. ( De Lorenzo, MS; Fukui, H; Gomez, DE; Ikenaka, Y; Kishida, H; Kuriyama, S; Nakae, D; Nakatani, T; Noguchi, R; Okuda, H; Tejera, AM; Tsujinoue, H; Yoshii, J; Yoshiji, H, 2001) |
| " When rabbits were daily injected intravenously with D-Pen at the per kilogram dosage administered to rheumatoid patients, neovascularization as quantitated by the proliferation of corneal new blood vessels was significantly inhibited." | 1.28 | Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. ( Hirohata, K; Matsubara, T; Saura, R; Ziff, M, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mammoto, T | 1 |
| Jiang, A | 1 |
| Jiang, E | 1 |
| Panigrahy, D | 1 |
| Kieran, MW | 1 |
| Mammoto, A | 1 |
| Sproull, M | 1 |
| Brechbiel, M | 1 |
| Camphausen, K | 1 |
| Girardot, D | 1 |
| Jover, B | 1 |
| Moles, JP | 1 |
| Deblois, D | 1 |
| Moreau, P | 1 |
| Brem, S | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| New, P | 1 |
| Phuphanich, S | 1 |
| Alavi, JB | 1 |
| Mikkelsen, T | 1 |
| Fisher, JD | 1 |
| Brewer, GJ | 1 |
| Yoshida, D | 1 |
| Ikeda, Y | 1 |
| Nakazawa, S | 1 |
| Vanchieri, C | 1 |
| Yoshii, J | 1 |
| Yoshiji, H | 1 |
| Kuriyama, S | 1 |
| Ikenaka, Y | 1 |
| Noguchi, R | 1 |
| Okuda, H | 1 |
| Tsujinoue, H | 1 |
| Nakatani, T | 1 |
| Kishida, H | 1 |
| Nakae, D | 1 |
| Gomez, DE | 1 |
| De Lorenzo, MS | 1 |
| Tejera, AM | 1 |
| Fukui, H | 1 |
| Brem, SS | 1 |
| Zagzag, D | 1 |
| Tsanaclis, AM | 1 |
| Gately, S | 1 |
| Elkouby, MP | 1 |
| Brien, SE | 1 |
| Matsubara, T | 1 |
| Saura, R | 1 |
| Hirohata, K | 1 |
| Ziff, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Penicillamine and Reduction of Copper for Angiosuppressive Therapy of Adults With Newly Diagnosed Glioblastoma[NCT00003751] | Phase 2 | 40 participants (Anticipated) | Interventional | 1999-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for penicillamine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Antiangiogenic therapy through copper chelation.
Topics: Angiogenesis Inhibitors; Animals; Chelating Agents; Chelation Therapy; Copper; Corneal Neovasculariz | 2003 |
Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Topics: Animals; Copper; Fibrosis; Humans; Inflammation; Molybdenum; Neoplasms; Neovascularization, Patholog | 2005 |
1 trial available for penicillamine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.
Topics: Brain Neoplasms; Chelating Agents; Copper; Diet Therapy; Female; Glioblastoma; Humans; Male; Middle | 2005 |
7 other studies available for penicillamine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.
Topics: Animals; Brain; Brain Neoplasms; Cell Count; Cell Line, Tumor; Collagen; Disease Progression; Gliobl | 2013 |
Chronic nitric oxide synthase inhibition prevents new coronary capillary generation.
Topics: Administration, Oral; Animals; Aorta; Blood Pressure; Body Mass Index; Body Weight; Capillaries; Car | 2004 |
Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model.
Topics: Animals; Brain Neoplasms; Cell Division; Cell Line; Chelating Agents; Copper; Gliosarcoma; Male; Mic | 1995 |
Cutting copper curbs angiogenesis, studies show.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Chelating Agents; Clinical Trials as Topic; Combined Modal | 2000 |
The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Cell Division; Chelating Agents; Copper; Female; Liver Neoplasms, Experimental; | 2001 |
Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Capillary Permeability; Cell Division; Copper; Diet; Fi | 1990 |
Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.
Topics: Catalase; Cell Division; Copper; Copper Sulfate; Disulfides; DNA Replication; Drug Synergism; Endoth | 1989 |